Navigation Links
NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
Date:9/28/2010

BASEL, Switzerland, Sept. 28 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES) discloses its list of licenses.

NEURO # 1

SymPath(R)

TO EVALUATE THE SYMPATHETIC NERVOUS SYSTEM THROUGH THE ENZYME, DOPAMINE Beta- HYDROXYLASE (DBH), THAT IS RELEASED WITH NORADRENALINE WITHIN THE BLOOD AND DISTINGUISH BETWEEN DEPRESSIVE STATES AND ANXIOUS DISORDERS.

NEURO # 2

AXIS(TM)

TO QUANTITATIVELY AND DIRECTLY EVALUATE THE HYPOTHALAMO-PITUITARY ADRENAL AXIS THROUGH ENDING MOLECULES FORMED FROM THE RELEASED ACTH WITHIN THE BLOOD AND ACTING ON DESMOLASE ENZYME ACTIVITY, REQUIRING CHOLESTEROL BIOAVAILABILITY.

NEURO # 3

TETRIC(TM)

TO UNDERSTAND THE RELATIONSHIP BETWEEN CONSTITUTIVE & INDUCTIVE DBH ENZYME IN ORDER TO DISCRIMINATE PSYCHOAFFECTIVE AND MENTAL DISTURBANCES, THROUGH SIEVING MOLECULAR WEIGHT.

NEURO #4 and #5

ARE ONE PLATFORM FOR ALL OF THEM: 5-HT / 5HIAA DA / DOPAC / HVA NA / VMA / A MELATONIN TO UNDERSTAND THE RELATIONSHIP BETWEEN NEUROTRANSMITTERS, THE TURNOVER OF THEIR METABOLITES, AND TO FIGURE OUT THE CLINICAL PREDOMINENCE

NEURO # 6

TRYPTYR

TO EVALUATE THE BIOAVAILIBILITY OF TWO MAIN NEURO-TRANSMITTERS SUBSTRATES AND THEIR IMPACT IN BRAIN 5-HT AND NA SYNTHESIS.

NEURO #7

DIVAN

TO EVALUATE THE BIOAVAILABILITY OF THE EIGHT (8) ELECTROLYTES AND THEIR RELATIONSHIPS INVOLVED IN THE CNS.

NEURO # 8

GACHA

TO EVALUATE THE GABA AND ACETHYLCHOLINE RELATIONSHIP AT THE CELLULAR ENERGETIC CAPACITY.

NEURO # 9

FREERAD

TO MEASURE THE FREE RADICALS AND DETERMINE THEIR PREDOMINANCE IN REGARDS TO THE AXIS ACTIVITY.

NEURO # 10

MAOS

TO DETERMINE THE MAO TYPE A OR B ACTIVITY AND TO DEFINE THE CLINICAL PATIENT PROFILE IN RESPECT TO EXPECTED DIAGNOSIS AND THERAPEUTIC APPROACHES.

NEURO # 11

NEURENDOM

TO DEFINE THE MALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.

NEURO # 12

NEURENDOF

TO DEFINE THE FEMALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.


'/>"/>
SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
2. Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
3. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
4. New York State Licenses Personalized Prescribing DNA Tests
5. OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays
6. Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
7. Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Eidogen-Sertanty Licenses TIP to the FDA
10. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
11. GeneGo Licenses MetaCore to Proteostasis Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board meeting ... I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space ... membership in ARCS Alumni Hall of Fame . ASTER Labs is a ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):